Background: Wixela Inhub (trademarks of Viatris, Inc.) is a dry powder inhaler (DPI) that delivers a fixed-dose combination of fluticasone propionate and salmeterol and is approved as a generic equivalent to Advair Diskus (trademarks of GlaxoSmithKline plc) for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The dosing performance of DPIs is dependent on the patient's inspiratory capability, which may be impacted in disease populations such as those with severe COPD. The objective of this study was to evaluate the in vitro dose delivery of fluticasone propionate and salmeterol from the Inhub inhaler with in vivo inhalation profiles of severe COPD patients, using two types of breathing simulator with different modes of operation.

中文翻译：

---

Wixela Inhub 吸入器的体外性能使用严重慢性阻塞性肺疾病患者的吸入概况

背景： Wixela Inhub（Viatris, Inc. 的商标）是一种干粉吸入器 (DPI)，可提供丙酸氟替卡松和沙美特罗的固定剂量组合，并被批准为 Advair Diskus（葛兰素史克公司的商标）的仿制药，用于治疗哮喘和慢性阻塞性肺病（COPD）。DPI 的剂量性能取决于患者的吸气能力，这可能会影响疾病人群，例如患有严重 COPD 的人群。本研究的目的是评估从 Inhub 吸入器中丙酸氟替卡松和沙美特罗的体外给药剂量与严重 COPD 患者的体内吸入曲线，使用两种具有不同操作模式的呼吸模拟器。